We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Urine Bicarbonate Test Offers Safe Quantification of CFTR Function in Cystic Fibrosis Patients

By LabMedica International staff writers
Posted on 02 Nov 2022

The management of cystic fibrosis has changed with the recent introduction of therapies that target the disease-causing mechanism. More...

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, including elexacaftor, tezacaftor, and ivacaftor, are novel drugs that either potentiate or correct CFTR channel dysfunction. They can partially restore CFTR function. Measurement of sweat chloride concentration is the most used method to assess CFTR function in vivo. However, sweat chloride only associates marginally with clinical disease features, is time consuming, requires experienced staff, and has large intraindividual variation. Many other biomarkers for CFTR exist but have complicated approaches that limit their clinical use. Now, a study of patients with cystic fibrosis has found that challenged urine bicarbonate excretion may offer a new, simple, and safe quantification of CFTR function and the extent of its pharmacologic improvement.

Renal dysfunction may be related to cystic fibrosis and may be measured through tests quantifying bicarbonate secretion in the kidney that occurs via pendrin, according to a study by researchers from Aarhus University (Aarhus, Denmark). CFTR is fully necessary for the function and regulation of pendrin, which in cystic fibrosis leads to an impaired ability to excrete excess bicarbonate. These patients have a reduced ability to increase renal base excretion after oral sodium bicarbonate loading, making a challenge test a potential option for drug treatment monitoring.

For the study, the researchers studied 50 adult patients with cystic fibrosis starting CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor to evaluate the association between challenged bicarbonate excretion and clinical characteristics at baseline, quantify the CFTR modulator drug–induced changes of challenged bicarbonate excretion after six months of treatment, and characterize the intraindividual variation in healthy adults. The researchers evaluated and quantified urine bicarbonate excretion after an acute oral sodium bicarbonate challenge before and six months after elexacaftor/tezacaftor/ivacaftor treatment.

The researchers found that challenged urine bicarbonate excretion was associated with cystic fibrosis disease characteristics. The use of elexacaftor/tezacaftor/ivacaftor increased bicarbonate excretion to about 70% of that seen in control participants. According to the researchers, their early-stage evaluation shows that that challenged urine bicarbonate excretion offers a new, simple, and safe functional assessment quantifying the biological consequences of reduced CFTR function and the extent of functional recovery after pharmacologic treatment.

Related Links:
Aarhus University 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.